Immune Response Corporation
Preclinical data support continued development of IR103 HIV drug candidate
Published in AIDS Weekly and Law, May 13th, 2004
The data presented showed that IR103, an immune-based therapy comprised of a gp120-depleted HIV-1 immunogen (Remune) and a second-generation immunostimulatory oligonucleotide adjuvant (Amplivax developed by Hybridon, Inc.[HBY]), demonstrated potent HIV-1 specific immunogenicity.
These data warrant continued development of IR103 as a potential therapy for individuals living with HIV.
"These experimental data on IR103...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
Source: AIDS Weekly and Law (2004-05-13)
More Articles from AIDS Weekly and Law
- Abbott Laboratories
AIDS researchers to Abbott: Norvir price increase cannot be tolerated - Guangzhou Center for Disease Control & Prevention
Antiretroviral agents may be useful for SARS prevention and treatment - U.S. National Institutes of Health
Effect of HIV infection on NK cell inhibitory receptors clarified - Violence
Rwanda: Aid plea for genocide rape survivors - World Bank
African ambassadors seeking international help for women's health in Africa - Academic Medical Centre, Amsterdam
Subtype-specific transcriptional promoters determine replication rate - More from this issue of AIDS Weekly and Law
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
